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Virus strains in the seasonal influenza vaccine for 
the 2014/15 northern hemisphere season remained 
unchanged from those in 2013/14. During spring 2014, 
drifted influenza A(H3N2) viruses, subgroup 3C.3a, 
were detected in Finland; another subgroup, 3C.2a, 
emerged in the 2014/15 season and has predominated. 
We monitored antibody responses against vaccine and 
epidemic strains (2013/14 and 2014/15) among Finnish 
healthcare workers after influenza vaccination with 
the 2013/14 vaccine. The data suggest reduced cross-
protection towards both subgroups of drifted A(H3N2) 
viruses. 
Early in the 2014/15 influenza season, drifted influ-
enza A(H3N2) viruses have predominated in Europe 
[1,2]. In Finland, the season started earlier in the 
year than the previous season did (December 2014 as 
opposed to January 2014). We characterised a subset 
of circulating 2013/14 and 2014/15 influenza A(H3N2) 
viruses genetically to monitor changes in the circulat-
ing strains. On the basis of the genetic changes iden-
tified, representatives of these strains were selected 
for serological study. The strains recommended by the 
World Health Organization (WHO)  for inclusion in the 
2014/15 trivalent influenza vaccine (TIV) for the north-
ern hemisphere [3] are the same as those in 2013/14 
[4]: A/California/07/2009, A/Texas/50/2012 and B/
Massachusetts/02/2012. By exploring the antibody 
responses to the 2013/14 TIV in Finnish healthcare 
workers (HCWs), we evaluated the seroprotection level 
against viruses included in TIV and compared it with 
vaccine-induced cross-protection towards selected epi-
demic virus strains from the 2013/14 and 2014/15 sea-
sons. Our findings suggest reduced cross-protection 
towards the two subgroups of drifted A(H3N2) viruses 
detected in Finland (genetic subgroups 3C.3a and 
3C.2).
Genetic characterisation of influenza 
A(H3N2) viruses in Finland in 2013/14 and 
2014/15
As part of virological surveillance of influenza in 
Finland, a subset of influenza A(H3N2)-positive sam-
ples from sites in a sentinel influenza surveillance net-
work and non-sentinel sites are  selected throughout 
the season for genetic characterisation on the basis of 
their geographical origin and temporal distribution.
The sentinel network consists of healthcare centres 
collecting specimens from patients with influenza-like 
illness or acute respiratory infection and most also 
report clinical data. Healthcare centres of garrisons, 
also included in the network, only collect specimens. 
While intensive-care units are also part of the network, 
collecting specimens only, they are not considered as 
sentinel sites, as their participation is not agreed in 
advance (unlike that of healthcare centres). Other non-
sentinel sites include clinical microbiology laborato-
ries, for example. 
Phylogenetic analysis of the haemagglutinin gene was 
performed as described previously [5]. Reference influ-
enza A(H3N2) virus sequences for the phylogenetic tree 
were obtained from the EpiFlu database of the Global 
Initiative on Sharing Avian Influenza Data (GISAID) 
(Table 1).
During the 2013/14 season, a total of 27 influenza 
A(H3N2) viruses were analysed: 25 belonged to group 
3C.3 and two to group 3C.2 (Figure 1, Table 1). Of the 
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Table 1A
Origin of the haemagglutinin sequence information of influenza A(H3N2) viruses included in the phylogenetic analysis
Isolate name Segment ID Country Collection date
Originating 
laboratory Submitting laboratory Authors
A/Alabama/05/2010 EPI278808 United States 2010-Jul-13
US Air Force School 
of Aerospace 
Medicine
Centers for Disease Control 
and Prevention
A/Athens GR/112/2012 EPI358885 Greece 2012-Feb-01 Hellenic Pasteur Institute
National Institute for 
Medical Research
A/Hong Kong/146/2013 EPI426061 Hong Kong (SAR) 2013-Jan-11
Government Virus 
Unit
National Institute for 
Medical Research
A/Hong Kong/5738/2014 EPI539806 Hong Kong (SAR) 2014-Apr-30
Government Virus 
Unit
National Institute for 
Medical Research
A/Iowa/19/2010 EPI335923 United States 2010-Dec-30 Iowa State Hygienic Laboratory
Centers for Disease Control 
and Prevention
A/Ireland/M28426/2013 EPI467996 Ireland 2013-Apr-02
National Virus 
Reference 
Laboratory
National Institute for 
Medical Research
A/Johannesburg/3495/2012 EPI405940 South Africa 2012-Jul-04
Sandringham, 
National Institute for 
Communicable D
National Institute for 
Medical Research
A/Madagascar/0648/2011 EPI319276 Madagascar 2011-Feb-21 Institut Pasteur de Madagascar
National Institute for 
Medical Research
A/Nebraska/4/2014 EPI539619 United States 2014-Mar-11
Centers for Disease 
Control and 
Prevention
National Institute for 
Medical Research
A/Norway/1186/2011 EPI326137 Norway 2011-Mar-16 Norwegian Institute of Public Health
National Institute for 
Medical Research
A/Norway/1330/2010 EPI302231 Norway 2010-Dec-03 WHO National Influenza Centre
National Institute for 
Medical Research
A/Norway/1903/2014 EPI539623 Norway 2014-May–20 WHO National Influenza Centre
National Institute for 
Medical Research
A/Perth/16/2009 EPI211334 Australia 2009
WHO Collaborating 
Centre for Reference 
and Research on 
Influenza
Centers for Disease Control 
and Prevention
A/Samara/73/2013 EPI460558 Russian Federation 2013-Mar-12
WHO National 
Influenza Centre 
Russian Federation
National Institute for 
Medical Research
A/Stockholm/18/2011 EPI326139 Sweden 2011-Mar-28
Swedish Institute for 
Infectious Disease 
Control
National Institute for 
Medical Research
A/Switzerland/9715293/2013 EPI540526 Switzerland 2013-Dec-06 National Institute for Medical Research
Centers for Disease Control 
and Prevention
A/Texas/50/2012 EPI391247 United States 2012-Apr-15
Texas Department 
of State Health 
Services-Laboratory 
Services
Centers for Disease Control 
and Prevention
A/Victoria/361/2011 EPI349106 Australia 2011-Oct-24 Melbourne Pathology
WHO Collaborating Centre 
for Reference and Research 
on Influenza
Deng, Y-M;
Caldwell, N;
Iannello, P;
Komadina, N.
A/Finland/385/2013 EPI502957 Finland 2013-Dec-11 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
A/Finland/404/2014 EPI556921 Finland 2014-Feb-06 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
A/Finland/410/2014 EPI556922 Finland 2014-Feb-26 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
A/Finland/428/2014 EPI556939 Finland 2014-Feb-17 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
A/Finland/433/2014 EPI557055 Finland 2014-Feb-07 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
A/Finland/437/2014 EPI557056 Finland 2014-Mar-24 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
A/Finland/438/2014 EPI557057 Finland 2014-Apr-03 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
A/Finland/439/2014 EPI557058 Finland 2014-Apr-23 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
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25 group 3C.3 viruses, six represented a new drifted 
A(H3N2) type, group 3C.3a viruses. In Finland, these 
viruses were first detected in February 2013.
At the beginning of the 2014/15 season, all nine influ-
enza A(H3N2) viruses analysed belonged to another 
drifted group, 3C.2a.
Monitoring antibody response after 
influenza vaccination in a cohort of 
healthcare workers
A total of 79 clinically healthy HCWs (12 men, 67 women), 
median age 46 years (range: 22–66), were recruited on 
a voluntary basis during autumn 2013 from the per-
sonnel of the Department of Medicine at the Helsinki 
University Hospital and the Viral Infections Unit at the 
National Institute for Health and Welfare, Helsinki. The 
employer vaccinated each participant with the 2013/14 
seasonal influenza vaccine, which was trivalent, non-
adjuvanted, containing the three WHO-recommended 
influenza virus strains. One dose was administered 
intramuscularly. Serum samples were collected before 
vaccination (day 0) and three weeks and six months 
after vaccination.
The study protocol was approved by the Ethic 
Committee of the Department of Medicine, Helsinki 
University Hospital (298/13/03/00/12) and the Finnish 
Medicines Agency (EudraCT 2012–003727–38). Written 
informed consent was provided by all participants.
The serum samples were tested by the haemaggluti-
nation inhibition (HI) test for the presence of antibod-
ies against TIV vaccine viruses and Finnish influenza 
virus isolates from the 2013/14 and 2014/15 seasons. 
TIV strains for the northern hemisphere 2013/14 
and 2014/15 seasons were A/California/07/2009 
(group 1), A/Texas/50/2012 (group 3C.1) and B/
Massachusetts/02/2012 (clade 2). For comparison, we 
also included B/Wisconsin/01/2010 (clade 3), the vac-
cine strain for the northern hemisphere 2012/13 sea-
son, and A/Switzerland/9715293/2013 (H3N2) (group 
3C.3a), the vaccine strain for the southern hemisphere 
2015 season. We also included A/Finland/420/2014 
(group 6B), which represented the Finnish A(H1N1)
pdm09 strain that circulated in 2013/14. In addition, 
A/Finland/385/2013 (2013/14), A/Finland/428/2014 
(2013/14) and A/Finland/464/2014 (2014/15) were 
selected as representative of circulating Finnish 
A(H3N2) viruses for groups 3C.3, 3C.3a and 3C.2a, 
respectively.
The assay was performed as previously described [6] 
using erythrocytes from turkeys for A(H1N1)pdm09 
viruses and guinea pigs for A(H3N2) and influenza B 
viruses. A(H3N2) viruses were assayed in the presence 
of 20 nM oseltamivir carboxylate (Roche). For statisti-
cal analyses, serum specimens with HI titres < 10 were 
assigned a titre value of 5. We calculated the geometric 
mean titres (GMT) with 95% confidence intervals and 
presumable seroprotection rate (using the commonly 
accepted European Medicines Agency criteria [7]: HI 
titre ≥ 1:40) for each virus. Statistical significance of 
Isolate name Segment ID Country Collection date
Originating 
laboratory Submitting laboratory Authors
A/Finland/440/2014 EPI557059 Finland 2014-Apr-28 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
A/Finland/461/2014 EPI557060 Finland 2014-Oct-22 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
A/Finland/462/2014 EPI557061 Finland 2014-Oct-08 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
A/Finland/463/2014 EPI557062 Finland 2014-Nov-20 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
A/Finland/464/2014 EPI557063 Finland 2014-Nov-24 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
A/Finland/465/2014 EPI557064 Finland 2014-Dec-01 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
A/Finland/466/2014 EPI557065 Finland 2014-Nov-21 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
A/Finland/467/2014 EPI557066 Finland 2014-Nov-24 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
A/Finland/468/2014 EPI557067 Finland 2014-Nov-27 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
A/Finland/469/2014 EPI557068 Finland 2014-Nov-27 National Institute for Health and Welfare
National Institute for 
Health and Welfare
Ikonen, N; 
Haanpää, M
All reference and Finnish haemagglutinin sequences are available from the Global Initiative on Sharing Avian Influenza Data (GISAID) EpiFlu 
database.
Table 1B
Origin of the haemagglutinin sequence information of influenza A(H3N2) viruses included in the phylogenetic analysis
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Figure 1
Phylogenetic analysis of the haemagglutinin sequences of influenza A(H3N2) viruses from Finnish surveillance data during 
two epidemic seasons, 2013/14 and 2014/15
All sequences included in the phylogenetic tree were 1,650 nucleotides long. The tree was constructed using the neighbour-joining method 
with Mega software version 5.1 and with 1,000 bootstrap replicates. Bootstrapping values ≥ 60 are shown. The viruses used in serological 
tests are in bold blue. In addition, the vaccine viruses for northern and southern hemisphere are shown in boxes. Arrowed lines represent the 
location of amino acid substitutions.
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differences was estimated using Student’s t-test 
(paired, two-tailed), with a significance level of p < 0.05.
For all virus strains tested, there was a significant 
(p < 0.01) increase in the GMTs of the antibody response 
three weeks after TIV vaccination (Table 2). At six 
months, the GMTs decreased by 39.4–46.2%, 24.4–
42.3% and 11.9–18.4% for influenza A(H1N1)pdm09, 
A(H3N2) and B viruses, respectively. The decrease was 
significant (p < 0.05 to p < 0.001) for both types influ-
enza A viruses.
 
The baseline seroprotection rate for A(H1N1)pdm09 
viruses was 57.0–58.2% (Figure 2). Three weeks after 
vaccination, the GMTs were higher for the recently cir-
culating A/Finland/420/2014 strain than for the vac-
cine strain (p < 0.05). Post-vaccination seroprotection 
rates were 89.6% and 85.7% for A/Finland/420/2014 
and A/California/07/2009 viruses, respectively.
The seroprotection rate for A(H3N2) vaccine virus A/
Texas/50/2012 was 60.8% before vaccination and 
87.0% three weeks after it. Three weeks post-vac-
cination, the GMTs were somewhat weaker for A/
Finland/385/2013, a Finnish representative of group 
3C.3 virus strains, than to the vaccine strain (p < 0.01). 
Significantly lower GMTs were detected for the group 
3C.3a strain A/Switzerland/9715293/2013 as well as 
the Finnish group 3C.3a strain A/Finland/428/2014 
and recently circulating group 3C.2a strain A/
Finland/464/2014 compared with the vaccine strain 
(p < 0.0001).
For drifted Finnish 3C.3a and 3C.2a viruses, base-
line seroprotection rates were low (8.9% and 1.3%, 
respectively) and fivefold reductions in GMTs (for both) 
were detected three weeks after vaccination, com-
pared with the vaccine strain. The reduction in GMTs 
for A/Finland/428/2014 (group 3C.3a) was in line with 
recently reported HI and neutralisation levels [8,9].
The baseline seroprotection rate for influenza B 
viruses was 26.6–27.8%. Three weeks after vaccina-
tion, very similar  seroprotection rates were seen for 
vaccine strains B/Massachusetts/2/12 (61.0%) and 
B/Wisconsin/01/2010 (59.7%), which both represent 
the Yamagata-lineage viruses but belong to different 
clades.
Discussion
During the 2013/14 season, the relative prevalence of 
A(H1N1)pdm09, A(H3N2) and B influenza viruses varied 
from one European country to another [10]. In Finland, 
A(H1N1)pdm09 viruses predominated but A(H3N2) 
viruses were also detected. Most of the circulating 
A(H1N1)pdm09 and A(H3N2) viruses corresponded well 
with those included in the seasonal TIV vaccine for that 
season. Viruses from patients requiring intensive care 
Table 2
Geometric mean titres against influenza A(H1N1)pdm09, A(H3N2) and B viral strains measured by haemagglutination 
inhibition test before and after vaccination of 79 healthcare workers with 2013/14 trivalent influenza vaccine, Finland
Influenza virus strain Group
Geometric mean titres (95% CIs)
Day 0 
n = 79
Day 21 
n = 77
Day 180
n = 72
A(H1N1)pdm09
A/California/07/2009a 1 31.5 (26.0–40.4) 63.9 (51.9–74.5) 38.8 (32.3–48.6)
A/Finland/420/2014 6B 34.8 (29.6–50.4) 85.3 (68.8–105.5) 45.9 (37.4–61.7)
A(H3N2)b
A/Texas/50/2012a 3C.1 33.2 (26.5–41.0) 70.3 (57.8–86.0) 50.7 (39.7–60.4)
A/Finland/385/2013 3C.3 25.3 (20.7–31.0) 46.5 (38.1–56.0) 26.8 (21.6–32.4)
A/Switzerland/9715293/2013c 3C.3a 11.4 (8.9–14.3) 19.5 (15.1–26.4) 12.1 (9.6–16.0)
A/Finland/428/2014 3C.3a 8.6 (7.3–10.0) 13.7 (11.7–17.8) 8.7 (7.5–10.2)
A/Finland/464/2014 3C.2a 7.6 (6.7–8.7) 12.3 (10.8–15.0) 9.3 (8.1–10.7)
B (Yamagata)
B/Massachusetts/02/2012a Clade 2 19.8 (16.3–24.5) 37.1 (31.2–44.3) 30.3 (24.7–37.1)
B/Wisconsin/01/2010d Clade 3 19.1 (15.8–23.2) 34.0 (28.4–40.7) 30.0 (25.1–35.7)
CI: confidence interval.
One dose of non-adjuvanted trivalent 2013/14 seasonal influenza vaccine was administered intramuscularly to Finnish healthcare workers. 
Day 0 refers to serum samples collected before vaccination.
a Vaccine strain, northern hemisphere season 2013/14 and 2014/15.
b Haemagglutination inhibition test with 20nM oseltamivir carboxylate (Roche).
c Vaccine strain, southern hemisphere season 2015.
d Vaccine strain, northern hemisphere season 2012/13. 
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were not proven genetically different from other circu-
lating viruses [11].
Representatives of influenza A(H3N2) groups 3C.2 
and 3C.3 were found in Europe in the 2013/14 season 
and since February 2014, two new genetic subgroups, 
3C.2a and 3C.3a, emerged in these clusters [8,10]. Both 
of these genetic subgroups contain viruses that show 
antigenic drift from the vaccine virus [1]. In Finland, 
infections caused by A(H3N2) genetic subgroup 3C.3a 
viruses were detected between February and April 
2014. Genetic subgroup 3C.2a viruses, in contrast, did 
not circulate in Finland during the 2013/14 season but 
only emerged in the 2014/15 season.
Drifted influenza A(H3N2) viruses have been circulating 
in the countries of the European Union and European 
Economic Area in the 2014/15 season. The majority 
of genetically characterised viruses belong to group 
3C.2a although 3C.3a viruses have also been detected 
[1]. In the United States (US), the Centers for Disease 
Control and Prevention has issued a health advisory 
notice regarding the circulation of drifted influenza 
A(H3N2) viruses in the US [12]. Early estimates of the 
current seasonal influenza vaccine effectiveness from 
the US and Canada suggest low effectiveness against 
circulating A(H3N2) viruses [13,14].
New antigenic A(H3N2) clusters appear on average 
every 3.3 years [15]. Seven amino acid locations have 
been shown to be responsible for the major antigenic 
changes in A(H3N2) viruses [16]. Subgroup 3C.2a and 
3C.3a viruses carry specific amino acid substitutions 
that drifted from the corresponding main groups. Both 
subgroups have a substitution at position 159, which 
has shown to be one of seven positions responsible for 
the major antigenic changes between 1968 and 2003 
A(H3N2) viruses [16].
In our analysis of antibody response, GMTs against the 
circulating A/Finland/428/2014 virus (a group 3C.3a 
A(H3N2) virus) were found to be significantly lower 
Seroprotection rate was defined as the percentage of participants with a haemagglutination inhibition titre ≥ 40. Day 0 refers to serum 
samples collected before vaccination.
a Vaccine strain, northern hemisphere season 2013/14 and 2014/15.
b Vaccine strain, southern hemisphere season 2015.
c Vaccine strain, northern hemisphere season 2012/13.
Figure 2
Seroprotection rates determined by haemagglutination inhibition test before and after vaccination of 79 healthcare workers 
with 2013/14 trivalent influenza vaccine, Finland
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than GMTs against the homologous A/Texas/50/2012 
vaccine virus. These results are in line with those 
from Finnish A(H3N2) variant strains tested in WHO 
Collaborating Centre for Reference and Research on 
Influenza, in London, United Kingdom, using HI and 
virus neutralisation assays [9] and previous serologi-
cal studies [8]. The pre-vaccination seroprotection 
rate of the HCWs we tested for this virus variant was 
only less than 10%. Even at three weeks after vaccina-
tion, the cross-protection rate was only less than 30% 
and decreased to less than 10% within 6 months.
The GMTs were found to be significantly lower against 
the currently circulating subgroup 3C.2a A(H3N2) virus 
A/Finland/464/2014 than against the homologous A/
Texas/50/2012 vaccine virus. Only one of the 79 HCWs 
tested had pre-existing seroprotective antibody lev-
els against this virus variant. Three weeks after vac-
cination, the cross-protection rate was 16.9% and 
decreased to less than 2% within six months. Subgroup 
3C.2a viruses have also shown to have poor reactivity 
with post-infection ferret antisera against vaccine virus 
A/Texas/50/2012 [17].
Although influenza A(H1N1)pdm09 viruses have under-
gone genetic changes from the A/California/07/2009 
strains present in the vaccine, the majority of epidemic 
viruses in Europe have been antigenically similar to the 
vaccine virus [2,10]. Our serological results indicate 
a strong vaccine-induced seroprotection rate against 
A(H1N1)pdm09 viruses. Consistent with this, more than 
half of the Finnish HCWs tested had pre-existing immu-
nity against A(H1N1)pdm09 viruses. This may be due to 
the history of sequential TIV vaccinations in the study 
group or natural infections by A(H1N1)pdm09 viruses.
We acknowledge at least a few limitations in our sero-
logical analysis. First, the number of HCWs included in 
the study was limited. Secondly, the HCWs we tested 
did not represent all age groups: thus the results do 
not necessarily apply to children or elderly individu-
als. Antibody responses to influenza A(H1N1)pdm09 
vaccination are age dependent [18] and low vaccine 
effectiveness against A(H3N2) has been reported 
among elderly persons [19]. For influenza B viruses, 
the overall impact of lineage-level mismatch between 
vaccine and circulating strains has been shown to be 
considerable, especially among children and adoles-
cents [20]. Thirdly, HCWs are often vaccinated more 
regularly than others (in Finland, influenza vaccination 
is recommended for all HCWs who come in contact with 
patients) and they are also at higher risk of contract-
ing influenza virus. The impact of repeated vaccination 
on vaccine effectiveness against influenza is still under 
investigation and discussion [21,22].
In conclusion, our serological data suggest that 
although the 2013/14 and 2014/15 TIV would protect 
against A(H1N1)pdm09 viruses, the protection against 
influenza A(H3N2) 3C.2a and 3C.3a virus variants would 
be suboptimal. The current epidemic situation in the 
northern hemisphere underlines the need to change 
the A(H3N2) component of the 2015/16 vaccine to a 
virus that represents one of the drifted groups. With 
minimal pre-existing immunity and a limited cross-
protective effect from the TIV, the population in the 
northern hemisphere may be more susceptible to the 
new influenza A(H3N2) virus variants during the cur-
rent 2014/15 season. However, influenza vaccination is 
strongly encouraged for HCWs, as well as for persons 
in risk groups, to reduce influenza disease burden and 
the spread of the epidemics. 
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